Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~Inclusion criteria to be checked at the screening visit (SC):~1. Toddlers, children and adolescents:~   Sub-Group 1: from 12 months to 3 years of age on the day of inclusion~   Sub-Group 2: from 4 to 6 years of age on the day of inclusion~   Sub-Group 3: from 7 to 9 years of age on the day of inclusion~   Sub-Group 4: from 10 to 12 years of age on the day of inclusion~   Sub-Group 5: from 13 to 15 years of age on the day of inclusion~2. Screening informed consent form signed by the parent(s) or other legal representative for all the subjects and by the adolescents (sub-group 5 only)~Inclusion criteria to be checked at the inclusion visit (V01):~1. Toddlers, children and adolescents:~   Sub-Group 1: from 12 months to 3 years of age on the day of inclusion~   Sub-Group 2: from 4 to 6 years of age on the day of inclusion~   Sub-Group 3: from 7 to 9 years of age on the day of inclusion~   Sub-Group 4: from 10 to 12 years of age on the day of inclusion~   Sub-Group 5: from 13 to 15 years of age on the day of inclusion~2. Inclusion informed consent form signed by the parent(s) or other legal representative for all the subjects and by the adolescents (sub-group 5 only)~3. Able to attend all scheduled visits and to comply with all trial procedures~4. Subject anti-HAV seronegative (IgG) according to the screening results (assay performed with local kit)~5. Subject HBsAg seronegative and ALT \<40 IU/l according to the screening results~Exclusion Criteria :~Exclusion criteria to be checked at the inclusion visit (V01):~1. Participation in another clinical trial in the 4 weeks preceding trial vaccination~2. Planned participation in another clinical trial during the present trial period~3. Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy~4. Systemic hypersensitivity to any of the vaccines components or history of a life-threatening reaction to the trial vaccines or a vaccine containing the same substances~5. Chronic illness at a stage that could interfere with trial conduct or completion~6. Blood or blood-derived products received in the past 3 months~7. Any vaccination in the 4 weeks preceding the trial vaccination~8. Any vaccination planned in the 4 weeks following the trial vaccination~9. History of hepatitis A infection (confirmed either clinically or serologically )~10. Previous vaccination against hepatitis A with the trial vaccine or another hepatitis A vaccine~11. Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination~12. History of /current seizures~13. Clinical or serological evidence of systemic illness including Hepatitis C and HIV~14. Febrile (axillary temperature ≥ 37.1°C) or acute illness

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete